Reduction In Cyst Growth For Patients With Polycystic Kidney Disease (PKD) Using Tolvaptan

A clinical study shows that a drug therapy involving Tolvaptan resulted in a 50% reduction in cyst growth for patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Polycystic Kidney Disease or PKD is a hereditary kidney disease that causes the kidneys to be filled up with cysts. Over time, the kidneys get larger and larger. This generally results in kidney failure.

People with PKD experience kidney pain, bleeding, infections and high blood pressure. It also may cause the appearance of cysts in the liver and the weakening of blood vessels in the brain which can result in an aneurysm.